Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production

Gastroenterology

Volumn 148, Issue 2, 2015, Pages 403-414.e7

  Phillips, Sandra ^a   Chokshi, Shilpa ^a   Chatterji, Udayan ^b   Riva, Antonio ^a   Bobardt, Michael ^b   Williams, Roger ^a   Gallay, Philippe ^b   Naoumov, Nikolai V ^c  

^a INSTITUTE OF HEPATOLOGY   (United Kingdom)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cyclophilin Inhibition; Direct Acting Antiviral Agent; Peptidyl Prolyl Isomerase; Viral Replication

Indexed keywords

ALISPORIVIR; CYCLOPHILIN; CYCLOPHILIN A; CYCLOPHILIN C; CYCLOPHILIN D; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; HEPATITIS B SURFACE ANTIGEN; SMALL INTERFERING RNA; TELBIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA; ANTIVIRUS AGENT; CYCLOSPORIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; GENE SILENCING; HEPARG CELL LINE; HEPATITIS B; HEPG2215 CELL LINE; HUH 7 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SOUTHERN BLOTTING; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; HEPATITIS B VIRUS; HEPG2 CELL LINE; PHYSIOLOGY;

ANTIVIRAL AGENTS; CYCLOPHILINS; CYCLOSPORINE; DNA, VIRAL; HEP G2 CELLS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; VIRUS REPLICATION;

EID: 84921340561     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.10.004     Document Type: Article

References (39)

1. P. Wang, and J. Heitman The cyclophilins Genome Biol 6 2005 226
2. K. Lin, and P. Gallay Curing a viral infection by targeting the host: the example of cyclophilin inhibitors Antiviral Res 99 2013 68 77
3. L.A. Gaither, J. Borawski, and L.J. Anderson Multiple cyclophilins involved in different cellular pathways mediate HCV replication Virology 397 2010 43 55
4. M. Dorner, J.A. Horwitz, and B.M. Donovan Completion of the entire hepatitis C virus life cycle in genetically humanized mice Nature 501 2013 237 241
5. A.P. Castro, T.M. Carvalho, and N. Moussatche Redistribution of cyclophilin A to viral factories during vaccinia virus infection and its incorporation into mature particles J Virol 77 2003 9052 9068
6. D. Zhou, Q. Mei, and J. Li Cyclophilin A and viral infections Biochem Biophys Res Commun 424 2012 647 650
7. Y.J. Li, H.H. Wu, and C.H. Weng Cyclophilin A and nuclear factor of activated T cells are essential in cyclosporine-mediated suppression of polyomavirus BK replication Am J Transplant 12 2012 2348 2362
8. S. Pfefferle, J. Schopf, and M. Kogl The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors PLoS Pathog 7 2011 e1002331
9. P.A. Gallay, and K. Lin Profile of alisporivir and its potential in the treatment of hepatitis C Drug Des Devel Ther 7 2013 105 115
10. L. Coelmont, S. Kaptein, and J. Paeshuyse Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors Antimicrob Agents Chemother 53 2009 967 976
11. U. Chatterji, M. Bobardt, and S. Selvarajah The isomerase active site of cyclophilin A is critical for hepatitis C virus replication J Biol Chem 284 2009 16998 17005
12. A. Kaul, S. Stauffer, and C. Berger Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics PLoS Pathog 5 2009 e1000546
13. L.J. Anderson, K. Lin, and T. Compton Inhibition of cyclophilins alters lipid trafficking and blocks hepatitis C virus secretion Virol J 8 2011 329
14. S. Phillips, S. Chokshi, and A. Riva CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions J Immunol 184 2010 287 295
15. A. Rang, S. Gunther, and H. Will Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells J Hepatol 31 1999 791 799
16. O. Hantz, R. Parent, and D. Durantel Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells J Gen Virol 90 2009 127 135
17. M. Seifer, A. Patty, and I. Serra Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir Antiviral Res 81 2009 147 155
18. S. Proto, J.A. Taylor, and S. Chokshi APOBEC and iNOS are not the main intracellular effectors of IFN-gamma-mediated inactivation of hepatitis B virus replication Antiviral Res 78 2008 260 267
19. E.M. Southern Detection of specific sequences among DNA fragments separated by gel electrophoresis J Mol Biol 98 1975 503 517
20. J. Sambrook, E.F. Fritsch, and T. Maniatis Molecular cloning: a laboratory Manual 1989 Cold Spring Harbor Laboratory Press New York
21. R. Flisiak, A. Horban, and P. Gallay The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus Hepatology 47 2008 817 826
22. M.L. McHugh Multiple comparison analysis testing in ANOVA Biochem Med (Zagreb) 21 2011 203 209
23. M. Dandri, and S. Locarnini New insight in the pathobiology of hepatitis B virus infection Gut 61 Suppl 1 2012 i6 i17
24. X. Tian, C. Zhao, and H. Zhu Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: possible link to pathogenesis of HBV infection J Virol 84 2010 3373 3381
25. M.J. Bouchard, L.H. Wang, and R.J. Schneider Calcium signaling by HBx protein in hepatitis B virus DNA replication Science 294 2001 2376 2378
26. J. Lucifora, S. Arzberger, and D. Durantel Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection J Hepatol 55 2011 996 1003
27. A.J. Clippinger, and M.J. Bouchard Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential J Virol 82 2008 6798 6811
28. M.J. Bouchard, R.J. Puro, and L. Wang Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication J Virol 77 2003 7713 7719
29. Y. Ni, F.A. Lempp, and S. Mehrle Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes Gastroenterology 146 2014 1070 1083
30. H. Yan, G. Zhong, and G. Xu Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus Elife 1 2012 e00049
31. S. Nkongolo, Y. Ni, and F.A. Lempp Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor J Hepatol 60 2014 723 731
32. K. Watashi, A. Sluder, and T. Daito Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP) Hepatology 59 2014 1726 1737
33. Y.F. Liaw, N. Leung, and J.H. Kao Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2 2008 263 283
34. EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
35. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
36. K. Wursthorn, M. Jung, and A. Riva Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients Hepatology 52 2010 1611 1620
37. S.J. Scaglione, and A.S. Lok Effectiveness of hepatitis B treatment in clinical practice Gastroenterology 142 2012 1360 1368
38. L. Griffel, W. Bao, and R. Orsenigo Interferon (IFN)-free alisporivir has a better overall safety profile compared to IFN-containing treatment: a pooled analysis of the ALV development program J Hepatol 58 Suppl 1 2013 S336 S337
39. A. Evans, A. Riva, and H. Cooksley Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion Hepatology 48 2008 759 769